Latest News and Press Releases

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...

BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been...

NEW YORK, NY--(Marketwired - Feb 5, 2014) - RAPP (www.rapp.com), a global customer experience agency, today announced the appointment of Rik Haslam to the position of SVP, Executive Creative...

NEW YORK, NY--(Marketwired - Dec 20, 2013) - RAPP, a global customer experience agency, today announced the appointment of Rose Cameron to the role of SVP, Experience Planning. This is a new...

LOS ANGELES, CA--(Marketwired - Aug 5, 2013) - RAPP, an Omnicom-owned global agency, today announced the appointment of Greg Andersen to the position of Managing Director of RAPP Los Angeles....

LOS ANGELES, CA--(Marketwire - Nov 6, 2012) -   Zihla Salinas, RAPP's U.S. Chief Business Development Officer, and Jessie Kernan, RAPP's U.S. Chief Strategy Officer, were both honored as...